Sign in

    James E. Davis

    Chairman, CEO, and President at Quest Diagnostics Inc
    Board
    Since November 1, 2022
    Age
    62 years
    Tenure
    Joined DGX in April 2013 as Senior Vice President and advanced through roles including Executive Vice President, CEO‐Elect on February 3, 2022, Chief Executive Officer and President on November 1, 2022, and ultimately as Chairman on April 1, 2023.

    Also at Quest Diagnostics Inc

    CTD
    Catherine T. Doherty
    Senior Vice President, Regional Businesses
    KK
    Karthik Kuppusamy
    Senior Vice President, Clinical Solutions
    MAG
    Mark A. Gardner
    Senior Vice President, Molecular Genomics and Oncology

    About

    At 62 years old as of fiscal year 2024, the executive has dedicated his career to advancing healthcare and diagnostics, consistently delivering strategic leadership in complex, global organizations.

    His professional journey at DGX began when he joined Quest Diagnostics on April 1, 2013 as Senior Vice President, Diagnostics Solutions, where he played a pivotal role in redefining diagnostic information services. Over time, he earned successive promotions, including a key role as Executive Vice President, followed by his appointment as CEO‐Elect on February 3, 2022 and then as Chief Executive Officer and President on November 1, 2022.

    Prior to his tenure at DGX, he demonstrated his executive acumen by serving as CEO at InSightec, Inc. and holding various senior positions at General Electric’s healthcare business, among other leadership roles. His career reflects a steadfast commitment to operational excellence, innovation, and transforming business strategies in the healthcare industry.

    $DGX Performance Under James E. Davis

    Past Roles

    OrganizationRoleDate RangeDetails
    Quest Diagnostics (DGX) CEO-ElectFeb 3, 2022 - Nov 1, 2022Predecessor role; ended upon promotion to Chairman, CEO, and President
    Quest Diagnostics (DGX) Executive Vice President, General DiagnosticsJan 2017 - (ended upon promotion)Managed a portfolio of businesses and refocused the company on diagnostic information services
    Quest Diagnostics (DGX) Senior Vice President, Diagnostics SolutionsApril 2013 - (subsequent transition)Focused on healthcare IT, risk assessment, clinical trials, diagnostic products, and employer solutions
    Quest Diagnostics (DGX) Products Business ManagerFeb 2014 - 2016Oversaw the products business
    Quest Diagnostics (DGX) General Management, Regional Diagnostic Information ServicesJanuary 2015 - (unclear end date)Assumed responsibility for the regional Diagnostic Information Services business
    InSightec, Inc. Lead Director and later Chief Executive OfficerMar 2012 - Apr 2013Led development of ultrasound ablation devices guided by MRI systems
    General Electric (GE) VP & GM, GE Healthcare’s MRI Business; also held leadership roles in aviation2007 - 2012Managed GE Healthcare's magnetic resonance imaging business and led strategic operational improvements in aviation
    McKinsey & Company, Inc. ConsultantN/ADeveloped strategic and operational improvement initiatives

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary (Actual Paid)$1,175,000 Paid throughout 2023 (adjusted timing)Fixed annual base salary
    Matching Contributions (401(k))$16,500 2023 per plan guidelinesMatching contributions under the 401(k) Plan
    Matching Credits (SDCP)$72,306 2023 per plan provisionsMatching credits under the Supplemental Deferred Compensation Plan (SDCP)

    Performance Compensation

    Data from  FY 2023

    Performance Shares

    MetricValue/ConditionDetails
    Weight for Revenue CAGR50% Includes COVID-19 revenues during performance period
    Weight for Average ROIC30% Specific targets undisclosed
    Weight for Relative TSR20% Payouts vary: ≥75th: 2x; 50th: 1x; 25th: 0.5x; <25th: 0x
    Threshold Award2,517 shares Minimum performance level
    Target Award33,562 shares Performance target
    Maximum Award67,124 shares Cap on award
    Vesting ScheduleVests after 3-year period ending Dec 31, 2025 Evaluation Period: Jan 1, 2023 – Dec 31, 2025
    Grant DateFeb 23, 2023
    Grant Date Fair Value$4,790,640
    Grant Date Stock Price$142.44

    Non-Equity Incentive Plan (SMIP)

    MetricValueDetails
    Threshold Payout$440,625 Minimum performance level
    Target Payout$1,762,500 Established target
    Maximum Payout$3,525,000 Cap on incentive payout
    Actual Payment$1,361,531 115.9% of target; 77.25% of salary
    Adjusted Diluted EPS$8.71 Factored into performance evaluation
    Payment BasisCash-basedAward paid annually; no vesting schedule
    Grant DateFeb 23, 2023

    Accelerated Vesting of Performance Shares

    MetricValue/ConditionDetails
    Accelerated Vesting Value$16,887,478 If termination occurs on Dec 31, 2023
    Vesting ConditionIf terminated on Dec 31, 2023Based on the greater of actual versus target performance